RLMD vs SLDB
RLMD: Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate. SLDB: A gene therapy company advancing a pipeline of treatments for rare neuromuscular and cardiac diseases including Duchenne muscular dystrophy, Friedreich's ataxia, and cardiomyopathy.
Side-by-side fundamentals
| Metric | RLMD | SLDB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $5.00 | $8.10 | |
| Market cap as of 2026-07-23 | $524M | $808M | |
| Net margin as of 2026-07-23 | -500.0% | -588.3% | RLMD higher |
| Gross margin as of 2026-07-23 | +0.0% | n/a | |
| Operating margin as of 2026-07-23 | -500.0% | -591.1% | RLMD higher |
| ROE as of 2026-07-23 | -71.2% | -74.5% | RLMD higher |
| ROA as of 2026-07-23 | -64.5% | -62.0% | SLDB higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 0.48 | 2.40 | |
| 1-year return as of 2026-07-22 close | +699.4% | +32.8% | RLMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.